Key result
Vancomycin achieves complete recovery at 3 months in community-acquired MRSA infective endocarditis.
Why the study?
Infective endocarditis caused by community-acquired methicillin-resistant Staphylococcus aureus not associated with healthcare contact had not previously been reported in Brazil, and the increasing incidence of CA-MRSA endocarditis challenges the choice of empirical therapy.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Alerts clinicians to CA-MRSA IE in healthy patients without healthcare exposure; leaves open optimal therapy and epidemiology for this entity.
We report here the first case of endocarditis due to CA-MRSA not associated with healthcare contact in Brazil in Brazil. A previously healthy patient presented with history of endocarditis following a traumatic wound infection. Patient had multiple positive blood cultures within 72 h of admission and met modified Duke's criterion for infective endocarditis. The isolate was typed as Staphylococcal cassette chromosome (SCC) mec type IV and was positive for presence of Panton-Valentine leukocidin (PVL). Increased incidence of CA-MRSA endocarditis is a challenge for the internist to choose the best empirical therapy. Several authors have suggested an empirical therapy with both a beta-lactam and an anti-MRSA agent for serious S. aureus infections. Our patient was treated with Vancomycin and made complete recovery in 3 months.
No takes yet. Share an insight, caveat, or question.
Fortes et al. (2008) conducted a case report in Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infective endocarditis (n=1). Vancomycin was evaluated on Complete clinical recovery. Vancomycin treatment resulted in complete recovery in 3 months for 1 patient with CA-MRSA infective endocarditis not associated with healthcare contact.
Synapse has enriched 10 related papers. Consider them for comparative context: